KAVL vs CNTX

Analysts rate Context Therapeutics Inc.

(CNTX) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Context Therapeutics Inc.

(CNTX) delivered a total return of -54. 3%, compared to -100. 0% for Kaival Brands Innovations Group, Inc. (KAVL). Over 10 years, the gap is even starker: CNTX returned -54. 3% versus KAVL's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Kaival Brands Innovations Group, Inc.

(KAVL) is the lower-risk stock at -0. 17β versus Context Therapeutics Inc. 's 0. 46β — meaning CNTX is approximately -379% more volatile than KAVL relative to the S&P 500.

On earnings-per-share growth, the picture is similar: Context Therapeutics Inc.

grew EPS 17. 4% year-over-year, compared to 6. 8% for Kaival Brands Innovations Group, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Context Therapeutics Inc.

(CNTX) is the more profitable company, earning 0. 0% net margin versus -356. 2% for Kaival Brands Innovations Group, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CNTX leads at 0. 0% versus -365. 3% for KAVL. At the gross margin level — before operating expenses — KAVL leads at 1037%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, KAVL (100.

0% yield) pays a dividend. CNTX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Kaival Brands Innovations Group, Inc.

(KAVL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 17), 100. 0% yield). Both have compounded well over 10 years (KAVL: -100. 0%, CNTX: -54. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (KAVL (Consumer Defensive) and CNTX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: KAVL is a small-cap income-oriented stock; CNTX is a small-cap quality compounder stock. KAVL pays a dividend while CNTX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.